Stroke is the most disabling neurological disorder and often causes spasticity. Transmucosal cannabinoids (tetrahydrocannabinol and cannabidiol (THC:CBD), Sativex) is currently available to treat spasticity-associated symptoms in patients with multiple sclerosis. Cannabinoids are being considered useful also in the treatment of pain, nausea and epilepsy, but may bear and increased risk for cardiovascular events. Spasticity is often assessed with subjective and clinical rating scales, which are unable to measure the increased excitability of the monosynaptic reflex, considered the hallmark of spasticity. The neurophysiological assessment of the stretch reflex provides a precise and objective method to measure spasticity. We propose a novel study to understand if Sativex could be useful in reducing spasticity in stroke survivors and investigating tolerability and safety by accurate cardiovascular monitoring.

A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity

MARINELLI, LUCIO;BALESTRINO, MAURIZIO;MORI, LAURA;PUCE, LUCA;ROSA, GIAN MARCO;SERRATI, CARLO;GANDOLFO, CARLO;ABBRUZZESE, GIOVANNI;TROMPETTO, CARLO
2017-01-01

Abstract

Stroke is the most disabling neurological disorder and often causes spasticity. Transmucosal cannabinoids (tetrahydrocannabinol and cannabidiol (THC:CBD), Sativex) is currently available to treat spasticity-associated symptoms in patients with multiple sclerosis. Cannabinoids are being considered useful also in the treatment of pain, nausea and epilepsy, but may bear and increased risk for cardiovascular events. Spasticity is often assessed with subjective and clinical rating scales, which are unable to measure the increased excitability of the monosynaptic reflex, considered the hallmark of spasticity. The neurophysiological assessment of the stretch reflex provides a precise and objective method to measure spasticity. We propose a novel study to understand if Sativex could be useful in reducing spasticity in stroke survivors and investigating tolerability and safety by accurate cardiovascular monitoring.
File in questo prodotto:
File Dimensione Formato  
57 Marinelli 2017 A randomised controlled cross-over double-blind pilot study protocol on THC_CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity.pdf

accesso aperto

Descrizione: Marinelli L, Balestrino M, Mori L, et al. A randomised controlled cross-over double-blind pilot study protocol on THC:CBD oromucosal spray efficacy as an add-on therapy for post-stroke spasticity. BMJ Open2017;7:e016843. doi:10.1136/bmjopen-2017-016843. This is an Open Access article distributed in accordance with the Creative Commons Attribution non-commercial (CC BY-NC 4.0) license, wich permits others to distribute, remix, adapt, build upon this work non commercially, aand license their derivate wworks on different terms, provioded the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/-
Tipologia: Documento in versione editoriale
Dimensione 489.41 kB
Formato Adobe PDF
489.41 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11567/875679
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 18
  • ???jsp.display-item.citation.isi??? 19
social impact